Company Overview and News

5
C / Citigroup, Inc. OFFERING SUMMARY

22m sec.gov
Citigroup Global Markets Holdings Inc. Guaranteed by Citigroup
C

5
C / Citigroup, Inc. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

57m sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supple
C

5
C / Citigroup, Inc. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

57m sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supple
C

5
C / Citigroup, Inc. PRICING SUPPLEMENT (Prospectus)

1h sec.gov
Citigroup Global Markets Holdings Inc. September 21, 2018
C

5
C / Citigroup, Inc. PRICING SUPPLEMENT (Prospectus)

1h sec.gov
Citigroup Global Markets Holdings Inc. September 21, 2018
C

6
BlackRock (BLK) Acquires Asset-Management Business in Mexico

3h zacks
Recently, BlackRock (BLK - Free Report) announced the completion of the acquisition of the asset-management business of Citibanamex, a subsidiary of Citigroup (C - Free Report) . The deal was announced in November 2017. Notably, all viable approvals by Mexican regulatory bodies were granted to the deal. The deal involved acquisition of nearly $34 billion in assets under management of Citibanamex across local fixed income, equity and multi-asset products.
BLK C LAZ

43
Amazon Stock Could See New Highs Coming out of Its Latest Dip

12h investorplace
Amazon.Com (NASDAQ:AMZN) stock is on one of its periodic swoons. Shares that traded at nearly $2,050 at the start of September were being offered before trading opened Sept. 18 as low as $1,907. On the face of it, that seems cheap for Amazon stock.
C AMZN AAPL NFLX WMT

53
Can IBM Stock Be Boosted by the Cloud, Blockchain, And AI?

12h investorplace
While the bull market continues – led by a variety of tech operators like Apple (NASDAQ:AAPL), Amazon.com (NASDAQ:AMZN), and Netflix (NASDAQ:NFLX) – IBM (NYSE:IBM) stock has been left out of the party. Actually, during the past five years, it has severely underperformed the indexes. For this period, the average annual return on IBM stock was a horrible -1.95%.
IBM BCS C AMZN AAPL NFLX MSFT ORCL ADBE

5
C / Citigroup, Inc. PRICING SUPPLEMENT (Prospectus)

15h sec.gov
Citigroup Global Markets Holdings Inc. September 20, 2018
C

5
C / Citigroup, Inc. PRICING SUPPLEMENT (Prospectus)

15h sec.gov
Citigroup Global Markets Holdings Inc. September 20, 2018
C

5
C / Citigroup, Inc. PRICING SUPPLEMENT (Prospectus)

16h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No
C

5
C / Citigroup, Inc. PRICING SUPPLEMENT (Prospectus)

16h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No
C

7
Indonesia eyes foreign firms for more mergers

16h thestar.com.my
Indonesian regulations make it difficult – though not impossible – for foreign banks to invest more than 40% in local lenders. Singapore’s DBS Group Holdings Ltd scrapped a bid to buy PT Bank Danamon Indonesia in 2013 after the ownership rule was introduced.
SMFG SMFNF D05 DBSDF 8306 MBFJF DBSDY C 8316 CGBBW MUFG MTU

8
IPhone XS Debut Wins Some Positive Early Wall Street Reviews

18h theedgemarkets
(Sept 25): Apple Inc. released two of its newest iPhones for sale over the weekend, and some upbeat comments from Wall Street helped lift the stock, which had petered out following a brief rally when the new models were unveiled earlier this month.
C VZA CGBBW AAPL VZ

5
Citigroup settles US robo-signing case tied to consumer bankruptcies

18h channelnewsasia
Citigroup Inc will pay US$5 million to address "robo-signed" proofs of claim filed in consumer bankruptcy cases involving 71,448 Macy's-branded credit card accounts, the U.S. Department of Justice announced on Monday.
C CGBBW

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to C / Citigroup, Inc. on message board site Silicon Investor.

The Trump Presidency The Trump Presidency The Trump Presidency Politics for Pros- moderated Politics for Pros- moderated Politics for Pros- moderated
Ride the Tiger with CD Ride the Tiger with CD Ride the Tiger with CD View from the Center and Left View from the Center and Left View from the Center and Left
A Real American President: Donald Trump A Real American President: Donald Trump A Real American President: Donald Trump Apple Inc. Apple Inc. Apple Inc.
Rare Earth Elements and Exotic Metals Rare Earth Elements and Exotic Metals Rare Earth Elements and Exotic Metals BTDG - B2Digital, Inc. BTDG - B2Digital, Inc. BTDG - B2Digital, Inc.
Biotech Valuation Biotech Valuation Biotech Valuation LDSR - Landstar, Inc. LDSR - Landstar, Inc. LDSR - Landstar, Inc.
CUSIP: 172967424